Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Ultra Seal Corporation
EIR
•Ultra Seal Corporation•June 29, 2018

Ultra Seal Corporation – FDA EIR, Jun 29, 2018

Record Details

An FDA inspection of Ultra Seal Corporation, a non-sterile drug packager in New Paltz, NY, was conducted from June 25-29, 2018. This routine GMP surveillance, performed under Compliance Program 7356.002B, identified five significant objectionable conditions, resulting in the issuance of a Form FDA 483. The company operates under the Federal Food, Drug, and Cosmetic Act. The primary issues included a lack of a comprehensive written program for assessing drug product stability, with samples for annual stability studies not loaded in 2016 and 2017 for various products, and no product-specific stability protocols. The company also failed to thoroughly review unexplained discrepancies, specifically five microbiology out-of-specification results for its purified water system, without adequately assessing the impact on affected drug products. Further violations involved the absence of written procedures for production and process controls, leading to inadequate packaging validation practices, such as grouping products without formal viscosity comparisons. Additionally, there were no established written procedures for equipment cleaning and maintenance, failing to address worst-case scenarios or maximum dirty/clean hold times in validation studies. Lastly, drug products were not stored under appropriate temperature conditions, as the warehouse’s temperature mapping had not been updated since structural modifications in 2006/2007. Ultra Seal Corporation’s management acknowledged the observations and committed to providing a written response within 15 working days, indicating plans to hire a consultant to address the stability program deficiencies.

Company
Ultra Seal Corporation
Inspection date
June 29, 2018
Product type
drugs
Office
New York District Office
People
  • Bijoy Panicker
  • Dennis P. Borrello
  • Donna Turcotte (company_representative)
  • Ken Sowa (recipient)
  • Dawn Borrello (company_representative)
View Company Profile

ID · 171cfaf0-015e-4ee2-94e2-ef3e00cf35c3

Violation Codes6
21 CFR 211.100(a)21 CFR 211.166(a)21 CFR 211.19221 CFR 211.142(b)21 CFR 820.5021 CFR 211.67(b)

Full citation text and observation details available on the Dashboard.

Other documents for Ultra Seal Corporation
  • 483 - 2023-09-20September 20, 2023
  • 483 - 2021-11-19November 19, 2021
  • WARNING_LETTER - 2021-09-14September 14, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ultra Seal Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.